Day One

Thursday June 27 2019

Day Two

Friday June 28 2019

Translating Causation To Treatment - Reviewing The Microbiome's Role In Drug Development

8.30

Patient Engagement Facilitates Drug Development: Starting & Ending with the Patient in Mind

 

Download the event guide for full session details

Bernat Olle
CEO
Vedanta Biosciences

Colleen Cutcliffe
CEO
Whole Biome

9.30

Healthy Infants Harbour Intestinal Bacteria That Protect Against Food Allergy

 

Download the event guide for full session details

Cathryn Nagler
Bunning Food Allergy
Professor
University of Chicago

10.00

Microbiome Tools & Trends for the Pharmaceutical Industry

 

Download the event guide for full session details

Julia Cope
Director of Scientific
Operations
Diversigen

10.30

Shotgun Sequencing & Strain-Level Analysis: Study Design for Pre-Clinical & Clinical Development

 

Download the event guide for full session details

Nur Hasan
Chief Scientific Officer
CosmosID

11.00

Morning Refreshments and Speed Networking

STREAM A:
STREAM A:
12.00 A Preclinical Assessment of a
Rationally Designed LBP		  

 

 

Esi Lamouse-Smith,
Director Early Development
Translational Medicine in Immunology,
Janssen Pharmaceuticals
12.30  

Translating Probiotic Research into LBP Drug Programs

  • The BioGaia group of companies covers all
    regulatory categories of the probiotic/ LBP/
    microbiome industry. Within the probiotic sector
    it is an integrated business from discovery to
    branded products.
  • BioGaia Pharma AB is a subsidiary analysing
    early stage research for drug development
    opportunities and taking candidates into next
    stage development
  • Challenges with translating to a drug program
    from probiotic discovery research
 Nigel Titford,
Chief Executive Officer,
Biogaia Pharma

 

STREAM B:
STREAM C: